Oruka Therapeutics CEO Lawrence Klein joins us to discuss how his company raised its first round of financing before competing with major players in the inflammation space. We also discuss the latest news in the life sciences, including the end of the Amylyx ALS saga, another use case for GLP-1s, and a hurdle in Verve’s gene editing plans.
Here’s where you ... Show More
Jun 18
406: New hope in treating Huntington's disease and a report card on RFK Jr.'s promises
This week: New hope for people living with Huntington’s disease, and a report card on RFK Jr.’s effort to remake health in America. The Food and Drug Administration reversed its opposition to a closely watched gene therapy for Huntington’s disease, clearing a path for its maker, ... Show More
36m 10s
Feb 2023
Healthspan, Lifespan, and the Biology of Aging
<p>In this cross-over episode from Bio Eats World, Kristen Fortney, cofounder and CEO of BioAge, joins Vijay Pande, founding partner of a16z Bio + Health, and Olivia Webb, editorial lead, to discuss the biology of aging, how she started a company, and some fun things — like how l ... Show More
36m 45s
Apr 2024
The Deal Room: Alphabet Weighs Offer for HubSpot & 3 Hot M&A Breakdowns!
<p>Join us this week in The Deal Room as we dissect the buzz surrounding Google's potential acquisition of HubSpot, a deal potentially valued at a $35bn. Discover the strategic reasoning behind it, potential synergies, and the looming antitrust hurdles.</p><br><p>We also take you ... Show More
43m 42s
Aug 2021
372: Biotech Billionaire Anne Wojcicki, Cofounder and CEO of 23andMe
You’ve heard data has the power to make or break a business. Nobody knows this more than Anne Wojcicki, co-founder of biotech giant 23andMe. After 15 years of leveraging data to build a game-changing company, Wojcicki made headlines this summer when she became the latest self-mad ... Show More
53m 20s
Apr 2020
Gilead Virus Treatment Is Promising But No Silver Bullet Yet
Sam Fazeli, Director of Research: EMEA for Bloomberg Intelligence, on Gilead's positive trial for a potential coronavirus treatment. Lisa Shalett, Chief Investment Officer: Wealth Management for Morgan Stanley, discusses why she wants clients to avoid S&P indices and to actively ... Show More
30m 3s
Apr 2021
Virtual Reaity Robots Will Be Operating On You: Vicarious CEO
Adam Sachs, CEO and co-Founder of Vicarious Surgical, a robotic surgical company backed by Bill Gates, on using robotics technology and virtual reality to perform surgical procedures. Rick Palacios, Principal, Director of Research at John Burns Real Estate Consulting, on the inve ... Show More
26m 29s